Literature DB >> 16497946

Successful stem cell therapy using umbilical cord blood-derived multipotent stem cells for Buerger's disease and ischemic limb disease animal model.

Sung-Whan Kim1, Hoon Han, Gue-Tae Chae, Sung-Hoon Lee, Sun Bo, Jung-Hee Yoon, Yong-Soon Lee, Kwang-Soo Lee, Hwon-Kyum Park, Kyung-Sun Kang.   

Abstract

Buerger's disease, also known as thromboangiitis obliterans, is a nonatherosclerotic, inflammatory, vasoocclusive disease. It is characterized pathologically as a panangiitis of medium and small blood vessels, including both arteries and adjacent veins, especially the distal extremities (the feet and the hands). There is no curative medication or surgery for this disease. In the present study, we transplanted human leukocyte antigen-matched human umbilical cord blood (UCB)-derived mesenchymal stem cells (MSCs) into four men with Buerger's disease who had already received medical treatment and surgical therapies. After the stem cell transplantation, ischemic rest pain suddenly disappeared from their affected extremities. The necrotic skin lesions were healed within 4 weeks. In the follow-up angiography, digital capillaries were increased in number and size. In addition, vascular resistance in the affected extremities, compared with the preoperative examination, was markedly decreased due to improvement of the peripheral circulation. Because an animal model of Buerger's disease is absent and also to understand human results, we transplanted human UCB-derived MSCs to athymic nude mice with hind limb ischemia by femoral artery ligation. Up to 60% of the hind limbs were salvaged in the femoral artery-ligated animals. By in situ hybridization, the human UCB-derived MSCs were detected in the arterial walls of the ischemic hind limb in the treated group. Therefore, it is suggested that human UCB-derived MSC transplantation may be a new and useful therapeutic armament for Buerger's disease and similar ischemic diseases.

Entities:  

Mesh:

Year:  2006        PMID: 16497946     DOI: 10.1634/stemcells.2005-0365

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  65 in total

1.  Buerger's disease (Thromboangiitis obliterans): a diagnostic challenge.

Authors:  Vanda Cristina Jorge; Ana Carolina Araújo; Carla Noronha; António Panarra; Nuno Riso; Manuel Vaz Riscado
Journal:  BMJ Case Rep       Date:  2011-09-13

2.  GD2 expression is closely associated with neuronal differentiation of human umbilical cord blood-derived mesenchymal stem cells.

Authors:  Hye Jin Jin; Hae Yun Nam; Yun Kyong Bae; Soo Yeon Kim; I Rang Im; Wonil Oh; Yoon Sun Yang; Soo Jin Choi; Seong Who Kim
Journal:  Cell Mol Life Sci       Date:  2010-02-18       Impact factor: 9.261

3.  Isolation and characterization of stem cells from the human parathyroid gland.

Authors:  Y-R V Shih; T K Kuo; A-H Yang; O K Lee; C-H Lee
Journal:  Cell Prolif       Date:  2009-05-29       Impact factor: 6.831

4.  Stem cell treatment for complicated diabetes.

Authors:  Jong Yoon Bahk; Hoon Han; Youn Soo Lee
Journal:  Int J Stem Cells       Date:  2008-11       Impact factor: 2.500

5.  Umbilical cord-derived mesenchymal stem cells for treating osteoarthritis of the knee: a single-arm, open-label study.

Authors:  Ismail Hadisoebroto Dilogo; Anissa Feby Canintika; Alberto Lastiko Hanitya; Jeanne Adiwinata Pawitan; Isabella Kurnia Liem; Jacub Pandelaki
Journal:  Eur J Orthop Surg Traumatol       Date:  2020-01-27

6.  Human embryonic stem cell-derived mesenchymal stromal cell transplantation in a rat hind limb injury model.

Authors:  Juha P Laurila; Lilja Laatikainen; Maria D Castellone; Parul Trivedi; Jari Heikkila; Ari Hinkkanen; Peiman Hematti; Mikko O Laukkanen
Journal:  Cytotherapy       Date:  2009       Impact factor: 5.414

7.  Mesenchymal stromal cells from human perinatal tissues: From biology to cell therapy.

Authors:  Karen Bieback; Irena Brinkmann
Journal:  World J Stem Cells       Date:  2010-08-26       Impact factor: 5.326

8.  Stem cells for reprogramming: could hUMSCs be a better choice?

Authors:  Paulina Duya; Yuhong Bian; Xiaoqian Chu; Yanjun Zhang
Journal:  Cytotechnology       Date:  2012-09-12       Impact factor: 2.058

Review 9.  Do mesenchymal stem cells function across species barriers? Relevance for xenotransplantation.

Authors:  Jiang Li; Mohamed B Ezzelarab; David K C Cooper
Journal:  Xenotransplantation       Date:  2012 Sep-Oct       Impact factor: 3.907

10.  A phase I study of human cord blood-derived mesenchymal stem cell therapy in patients with peripheral arterial occlusive disease.

Authors:  Shin-Seok Yang; Na-Ri Kim; Kwang-Bo Park; Young-Soo Do; Kyounghwan Roh; Kyung-Sun Kang; Dong-Ik Kim
Journal:  Int J Stem Cells       Date:  2013-05       Impact factor: 2.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.